Sartorius grows in strong double digits in order intake, sales revenue and earnings
![](/46/pdcnewsitem/03/75/94/sart.png)
Expansion of Bioprocess Solutions stronger than expected yet again; positive development in Lab Products & Services.
Sartorius closed the first 9 months of 2015 with significant double-digit gains in order intake, sales revenue and earnings. Group order intake rose 19.9%, excluding currency effects, to 856.6 million euro; the reported figure surged 30.2%. Its sales revenue climbed 18.5% in constant currencies to 830.3 million euro (reported: 28.6%). Up 46.9%, operating profit grew even more strongly than sales revenue; the group's respective underlying EBITDA margin was 23.3% after 9 months. Based on the company’s excellent 9-month results, management raised its forecast again for the full year of 2015.
"The very strong growth of Bioprocess Solutions, our largest division, continued, which was due on the one hand to the excellent and better-than-expected market environment and, on the other hand, to our ongoing gains in market share," commented Group CEO Dr Joachim Kreuzburg on the company's 9-month results. "Our Lab Products & Services Division has also been recording solid growth. For the final quarter, we continue to expect high business performance. In our full-year forecast, we are now projecting a gain of approximately 15% in group sales and a consolidated underlying EBITDA margin of around 23% in constant currencies."
Business development of the divisions and regions
In view of the divisions, the Bioprocess Solutions Division that supplies products for the manufacture of biopharmaceuticals again proved to be the growth engine. The division's order intake rose sharply by 26.5% in constant currencies (reported: 38.4%) to 637.2 million euro, while its sales revenue increased 24.2% (reported: 35.9%) to 604.3 million euro. All product segments contributed to the division's strong growth; demand for single-use product solutions was especially high. BioOutsource Ltd and Cellca GmbH acquired in the reporting year also performed very well and contributed around one percentage point in constant currencies to the division's sales expansion.
For the Lab Products & Services Division, which supplies premium laboratory instruments and lab consumables, order intake in constant currencies rose 4.6% (reported: 11.0%) to 219.5 million euro. Its sales revenue was up 6.0% to 226.0 million euros (reported: 12.5%).
All regions contributed significant double-digit gains in sales revenue to the dynamic development of the Group. Business in the Americas increased at the highest rates, with an uptick in sales of 24.2%. Sales revenue with customers in the EMEA region rose 16.8%, and in the Asia | Pacific region, 14.7%.
Substantial gain in profitability
The Sartorius Group increased its underlying EBITDA overproportionately relative to sales revenue, by 46.9% to 193.8 million euro. A major reason for this was economies of scale; the favorable currency environment additionally had a positive effect. The group's corresponding margin was 23.3%, up from 20.4% a year ago. Earnings contributed by the Bioprocess Solutions Division climbed to 158.7 million euro; its respective margin rose year over year from 23.2% to 26.3%. The Lab Products & Sales Division also continued to improve its profitability, reporting an underlying EBITDA of 35.1 million euro following on 29.0 million euro in the previous year. This equates to a margin of 15.5%, up from 14.4% in the respective prior-year period.
Group EBIT, including extraordinary items of -6.7 million euro (9M 2014: -4.0 million euro), depreciation and amortization, was 146.6 million euros, reflecting a gain of 62.6%. The corresponding earnings margin rose from 14.0% in the year-earlier period to 17.7%. Relevant net profit for the Group jumped from 46.6 million euro to 78.9 million euro. Consolidated earnings per ordinary share were 4.62 euro (9M 2014: 2.73 euros), and per preference share, 4.64 euro (9M 2014: 2.75 euro).
Forecast raised
Based on the company's excellent performance in the first nine months, management raised its sales and earnings forecast for the full year of 2015. For the group, the company now expects sales to grow approximately 15% in constant currencies (previous guidance: approximately 12%). This sales figure includes around one percentage point projected to be contributed by the acquisitions of BioOutsource and Cellca. The company's underlying EBITDA margin is forecasted to reach around 23% in constant currencies; previously, around 22.5% was anticipated. Sartorius continues to plan on investing around 10% of its sales revenue.
In view of the two divisions, Sartorius anticipates that currency-adjusted sales revenue for Bioprocess Solutions will grow approximately 20% (previous guidance: approximately 15%). Of this percentage, around 1.5 percentage points are forecast to be contributed by the two acquisitions. The underlying EBITDA margin of Bioprocess Solutions is projected to attain around 26% (previous guidance: around 25.5%). For the Lab Products & Services Division, the company continues to forecast approximately 5% sales growth and an underlying EBITDA margin of around 15.5%.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance